MedTrace Logo

Low Grade Inflammation, Gut Microbiota and Barrier Function in Elderly Humans

NCT01218165 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-10-28

No results posted yet for this study

Summary

Cardiovascular diseases (CVD) are the main cause of death in the European Union. A large part of the aging process, including immunosenescence, is explained by an imbalance between inflammatory and anti-inflammatory networks, wich results in the low grade chronic pro-inflammatory status termed inflammaging. It can contribute to a number of age-related chronic diseases (e.g. atherosclerosis, type 2 diabetes, Alzheimer disease, osteoporosis). Prevention or delay in onset of chronic diseases can potentially benefit a large segment of the elderly population. Now it is hypothesised that a probiotic drink can reduce low-grade inflammation through improvement of the gut barrier function and gut microbiota composition in elderly people with low-grade inflammation.

Conditions

  • Aged
  • Healthy

Interventions

DIETARY_SUPPLEMENT

Probiotic drink

This group receives a probiotic drink daily for 6 week.

OTHER

Control Group

without intervention

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Luzia Valentini, Doctor · Charite University, Berlin, Germany

  • Herbert Lochs, Professor · Medical University of Innsbruck

  • Jörg-Dieter Schulzke, Professor · Charite University, Berlin, Germany

  • Stefan Bereswill, Professor · Charite University, Berlin, Germany

  • Alexander Swidsinski, Doctor · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-11-30
Completion
2011-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01218165 on ClinicalTrials.gov